DEF 14C: Natures Miracle Holding Inc. Secures Shareholder Approval for Public Offering via Written Consent

Natures Miracle Holding Inc. obtained majority shareholder approval via written consent for a public offering to maintain Nasdaq listing compliance.

Summary

• Natures Miracle Holding Inc. is informing shareholders about the approval of a public offering that closed on November 12, 2024.
• The approval was secured through written consents from majority shareholders, representing approximately 56.9% of the voting power.
• The offering included the issuance of units, pre-funded units, and warrants to purchase common stock.
• The company raised approximately $2.5 million in net proceeds from the offering.
• The offering was necessary to comply with Nasdaq listing rules, specifically rule 5635(d), due to the potential issuance of shares underlying the warrants.
• The warrants are exercisable upon shareholder approval, which is being provided through this information statement, and have varying exercise prices and terms.
• The Series A warrants have an exercise price of $0.1118 per share, while the Series B warrants have an exercise price of $0.0001 per share, with the number of shares issuable under the Series B Warrants determined after a reset period.
• The maximum number of shares of Common Stock underlying the Series A Warrants would be an aggregate of approximately 134,168,157 and the maximum number of shares of Common Stock underlying the Series B Warrants would be an aggregate of approximately 107,334,526.

Sentiment

Score: 7

Explanation: The document is factual and reports on a necessary step for the company to maintain its listing. The sentiment is neutral to slightly positive as the company has successfully raised capital and is complying with regulations.

Positives

• The company successfully completed a public offering, raising $2.5 million in net proceeds.
• The offering ensures compliance with Nasdaq listing rules.
• The use of written consent allowed for swift approval of the offering.
• The offering provides the company with additional capital.

Negatives

• The offering was categorized as a private placement due to the potential for the exercise price of the warrants to be less than 50% of the minimum price.
• The company incurred underwriting discounts and commissions equal to 7.0% of the gross proceeds of the Offering and a non-accountable expense fee equal to 0.5% of the gross proceeds of the Offering.
• The exercise of the warrants is contingent on shareholder approval, which is being provided through this information statement.

Risks

• The exercise of warrants could significantly dilute existing shareholders.
• The company is dependent on shareholder approval for the warrants to become exercisable.
• The reset price of the Series B warrants is subject to market fluctuations.
• The company may need to raise additional capital in the future.

Future Outlook

The company anticipates the warrants will become exercisable 20 days after the mailing of this information statement, pending shareholder approval. The company will continue to operate as a publicly listed company on the Nasdaq.

Management Comments

• The Board of Directors is providing this information statement to inform shareholders of the actions taken by the majority shareholders.
• The company is not requesting a proxy from shareholders.

Industry Context

This announcement is typical for companies needing to raise capital while maintaining compliance with stock exchange listing rules. The use of warrants is a common method to attract investors in such offerings.

Comparison to Industry Standards

• The use of a firm commitment underwritten public offering is a standard practice for companies seeking to raise capital.
• The offering structure, including units with common stock and warrants, is a common approach in the small-cap market.
• The underwriting discount of 7.0% and a non-accountable expense fee of 0.5% are within the typical range for similar offerings.
• The need for shareholder approval for warrant exercise is a standard requirement under Nasdaq listing rules, similar to other companies listed on the exchange.

Stakeholder Impact

• Shareholders are being informed of the actions taken by the majority shareholders.
• The offering will dilute existing shareholders if the warrants are exercised.
• The company has secured additional capital which may benefit the company and its stakeholders.

Next Steps

• The company will mail the Notice of Shareholder Action by Written Consents to the Shareholders on or about November 27, 2024.
• The warrants will become exercisable 20 days after the mailing of this information statement, pending shareholder approval.

Key Dates

Keywords

public offering, warrants, Nasdaq listing, shareholder approval, written consent, common stock, underwriting, private placement, dilution